Not a good buy right now for an impatient trader: trend is bearish (SMA_200 > SMA_20 > SMA_5) and momentum is weakening (MACD histogram negative and expanding).
Price is sitting on/just above key support (~0.531); a breakdown likely invites a quick drop toward ~0.501 (S2), which is unfavorable for immediate entries.
No Intellectia buy signals today (AI Stock Picker / SwingMax), so there’s no proprietary edge to override the weak technical setup.
News flow is constructive (patent + clinical narrative), but the next truly meaningful catalyst (Phase 2b HLHS readout in Q3 2026) is not near-term, which doesn’t match an impatient profile.
Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5), implying sustained downtrend pressure.
Momentum: MACD histogram at -0.00107 (below 0) and negatively expanding → bearish momentum is strengthening, not improving.
RSI(6): 39.33 (neutral-to-weak); not oversold enough to suggest a high-conviction rebound.
Levels: Immediate support S1 ~0.531 (current ~0.532). If lost, next support S2 ~0.501. Overhead resistance/pivot is ~0.58, then ~0.629.
Pattern-based projection provided: modest positive skew (next week/month), but it conflicts with the current bearish MA/MACD setup—treat as lower-confidence until price reclaims the pivot (~0.58).
Positive Catalysts
strengthens moat/credibility for the platform.
Neutral/Negative Catalysts
Clear technical downtrend with weakening momentum; poor timing for immediate buys without a reversal signal.
Micro-cap profile (market cap shown ~$11.66M) often brings liquidity risk and sharp downside on disappointing updates.
Revenue volatility: latest quarter shows a steep revenue drop YoY, which can weigh on sentiment and financing expectations.
Key clinical catalyst (HLHS Phase 2b readout) is far out (Q3 2026), offering limited near-term fundamental support for an impatient entry.
No notable hedge fund/insider accumulation trend reported recently (neutral activity).
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 137,000, down 82.28% YoY (strong negative growth signal).
Net income: -7.221M, improved 58.08% YoY (loss narrowed vs prior year period).
Gross margin: 91.24%, up 3.41% YoY (high margin, but revenue base is very small and volatile).
Overall: financials reflect a development-stage biotech—improving losses, but weak/unstable revenue trend.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating / price target change data was provided in the dataset, so a recent trend in upgrades/downgrades cannot be confirmed here.
Wall Street-style pros (typical for this setup): differentiated cell-therapy platform, expanding IP portfolio, and a defined pivotal trial pathway (HLHS) that could re-rate the stock on positive data.
Wall Street-style cons: binary clinical/regulatory risk, ongoing losses and likely funding needs, and weak current technicals/low market cap that can amplify downside.
Influential/political flows: No recent congress trading data available; no politician buy/sell information indicated.
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.5 USD with a low forecast of 3 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 3.5 USD with a low forecast of 3 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.511
Low
3
Averages
3.5
High
4
Current: 0.511
Low
3
Averages
3.5
High
4
Roth Capital
Buy
downgrade
$10 -> $3
AI Analysis
2025-08-15
Reason
Roth Capital
Price Target
$10 -> $3
AI Analysis
2025-08-15
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on Longeveron to $3 from $10 and keeps a Buy rating on the shares. The firm's price target cut reflects Q2 results and the dilutive equity financing earlier this week, though Longeveron remains an underappreciated firm despite its first-mover advantage in HLHS, or Hypoplastic Left Heart Syndrome, the analyst tells investors in a research note.
